Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 14.48
+0.52 (3.72%)
Oct 23, 2026, 3:04 PM CST
SHE:300497 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 7,800 | 8,139 | 4,492 | 5,042 | 7,110 | 8,887 | |
Market Cap Growth | 37.12% | 81.17% | -10.90% | -29.09% | -19.99% | 34.93% |
Enterprise Value | 8,925 | 9,245 | 5,432 | 5,887 | 7,337 | 8,195 |
Last Close Price | 13.96 | 15.07 | 8.32 | 9.33 | 13.16 | 16.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 53.14 | - | - | - | - | 181.99 |
Forward PE | 10.82 | 29.64 | 29.64 | 29.64 | 29.64 | 19.92 |
PS Ratio | 4.82 | 6.87 | 3.81 | 3.13 | 4.32 | 6.22 |
PB Ratio | 3.16 | 3.70 | 2.06 | 2.04 | 2.64 | 3.05 |
P/TBV Ratio | 3.64 | 4.29 | 2.31 | 2.25 | 2.93 | 3.39 |
P/FCF Ratio | - | - | 97.89 | - | - | - |
P/OCF Ratio | 61.98 | 129.86 | 23.94 | - | - | 122.88 |
PEG Ratio | - | 0.73 | 0.73 | 0.73 | 0.73 | 0.73 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.55 | 7.80 | 4.61 | 3.66 | 4.45 | 5.73 |
EV/EBITDA Ratio | 25.04 | 63.29 | - | - | 113.16 | 30.17 |
EV/EBIT Ratio | 56.44 | - | - | - | - | 47.35 |
EV/FCF Ratio | - | - | 118.36 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.67 | 0.75 | 0.74 | 0.66 | 0.53 | 0.34 |
Debt / EBITDA Ratio | 4.63 | 11.30 | - | - | 21.87 | 3.69 |
Debt / FCF Ratio | - | - | 34.97 | - | - | - |
Net Debt / Equity Ratio | 0.46 | 0.53 | 0.42 | 0.36 | 0.14 | -0.14 |
Net Debt / EBITDA Ratio | 3.21 | 7.99 | -79.63 | -83.97 | 6.02 | -1.55 |
Net Debt / FCF Ratio | -28.68 | -7.19 | 19.77 | -2.92 | -0.67 | 0.69 |
Asset Turnover | 0.34 | 0.27 | 0.25 | 0.33 | 0.34 | 0.33 |
Inventory Turnover | 2.58 | 2.49 | 2.63 | 2.98 | 2.96 | 2.83 |
Quick Ratio | 0.99 | 0.84 | 0.81 | 1.11 | 1.32 | 1.38 |
Current Ratio | 1.28 | 1.15 | 1.09 | 1.46 | 1.77 | 1.70 |
Return on Equity (ROE) | 5.20% | -2.88% | -12.07% | -8.65% | -5.86% | 1.33% |
Return on Assets (ROA) | 2.09% | -0.57% | -2.44% | -2.15% | -0.76% | 2.48% |
Return on Invested Capital (ROIC) | 4.44% | -1.27% | -5.66% | -5.28% | -2.12% | 5.80% |
Return on Capital Employed (ROCE) | 4.60% | -1.30% | -6.10% | -4.80% | -1.60% | 5.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.88% | -0.68% | -6.06% | -3.98% | -1.99% | 0.55% |
FCF Yield | -0.51% | -1.99% | 1.02% | -6.09% | -8.16% | -6.83% |
Payout Ratio | 41.80% | - | - | - | - | 285.02% |
Buyback Yield / Dilution | 20.98% | -3.14% | 1.69% | 0.26% | -0.29% | -17.25% |
Total Shareholder Return | 21.70% | -3.14% | 1.69% | 0.26% | -0.29% | -17.25% |